ZBH / Zimmer Biomet Holdings, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Циммер Биомет Холдингс, Инк.
US ˙ NYSE ˙ US98956P1021

Основная статистика
LEI 2P2YLDVPES3BXQ1FRB91
CIK 1136869
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zimmer Biomet Holdings, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
September 4, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 ZIMMER BIOMET H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com

August 7, 2025 EX-99.1

Zimmer Biomet Announces Second Quarter 2025 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Kristen Cardillo David DeMartino (925) 786-4913 (646) 531-6115 [email protected] [email protected] Kirsten Fallon Zach Weiner (781) 779-5561 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces Second Quarter 2025 Financial Results • Secon

August 7, 2025 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of June 30, 2025 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International, Inc. Delaware Biomet Manufacturing, LLC Ind

August 7, 2025 10-Q

SECURITIES AND EXCHANGE COMMISSION FOR THE QUARTERLY PERIOD ENDED June 30, 2025 June 30, 2025 Page Part I - Financial Information Part II - Other Information Signatures 40 1. Basis of Presentation 2. Significant Accounting Policies

` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2025 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation

August 7, 2025 8-K

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis

July 14, 2025 EX-99.1

Disclaimer Cautionary Note Regarding Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including any statements

EX-99.1 MOVING YOU FORWARD July 14, 2025 ZBH Acquisition of Monogram Technologies Inc. Exhibit 99.1 Disclaimer Cautionary Note Regarding Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including any statements about us; Monogram Technologies Inc. (“Monogram”);

July 14, 2025 EX-99.2

Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to

EX-99.2 Exhibit 99.2 Zimmer Biomet: Media Kristen Cardillo 925-786-4913 [email protected] Kirsten Fallon 781-779-5561 [email protected] Investors David DeMartino 646-531-6115 [email protected] Zach Weiner 908-591-6955 [email protected] Monogram Technologies: Media and Investors: Chris Tyson MZ North America Direct 949-4791-8235 [email protected]

July 14, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 ZIMMER BIOMET HOLDI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commiss

June 30, 2025 EX-10.1

Five-Year Revolving Credit Agreement, dated as of June 27, 2025, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

Exhibit 10.1 EXECUTION VERSION FIVE-YEAR REVOLVING CREDIT AGREEMENT dated as of June 27, 2025, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURIT

June 30, 2025 8-K

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commiss

June 30, 2025 EX-10.2

364-Day Revolving Credit Agreement, dated as of June 27, 2025, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

Exhibit 10.2 EXECUTION VERSION 364-DAY REVOLVING CREDIT AGREEMENT dated as of June 27, 2025, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURITIE

June 20, 2025 EX-FILING FEES

Filing Fee Table.

Calculation of Filing Fee Tables S-8 ZIMMER BIOMET HOLDINGS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.01 par value per share, 2009 Stock Incentive Plan Other 10,000,000 $ 91.04 $ 910,400,00

June 20, 2025 S-8

As filed with the Securities and Exchange Commission on June 20, 2025

S-8 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No.

June 3, 2025 EX-10.1

Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed June 3, 2025).

Exhibit 10.1 ZIMMER BIOMET HOLDINGS, INC. 2009 STOCK INCENTIVE PLAN (As Amended on May 29, 2025) 1. GENERAL. (a) Establishment of Plan; Merger of Prior Plans. The Zimmer Holdings, Inc. 2009 Stock Incentive Plan (now known as the Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan) (the “Plan”) originally became effective on May 4, 2009 (the “2009 Effective Date”) as a successor to the Zimmer Ho

June 3, 2025 8-K

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissi

June 3, 2025 EX-3.1

Certificate of Amendment of Restated Certificate of Incorporation of Zimmer Biomet Holdings, Inc., dated May 29, 2025.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ZIMMER BIOMET HOLDINGS, INC. Zimmer Biomet Holdings, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Resta

June 3, 2025 EX-3.2

Restated Certificate of Incorporation of Zimmer Biomet Holdings, Inc., dated May 29, 2025.

Exhibit 3.2 RESTATED CERTIFICATE OF INCORPORATION OF ZIMMER BIOMET HOLDINGS, INC. The corporation was incorporated under the name “Zodiac Holdings, Inc.” by the filing of its original Certificate of Incorporation with the Secretary of State of Delaware on January 12, 2001 (the “Original Certificate of Incorporation”). The corporation filed a Certificate of Amendment of the Original Certificate of

May 27, 2025 EX-10.5

Employee Non-Disclosure, Trade Secret and Intellectual Property Agreement, dated as of May 24, 2025, by and between Zimmer Biomet Holdings, Inc. and Kevin Thornal.

EX-10.5 Exhibit 10.5 EMPLOYEE NON-DISCLOSURE, TRADE SECRET AND INTELLECTUAL PROPERTY AGREEMENT This Employee Non-Disclosure, Trade Secret and Intellectual Property Agreement (“Agreement”) is made and entered into by and between Zimmer Biomet Holdings, Inc., a corporation having its principal headquarters in Warsaw, Indiana, and Kevin Thornal (“Employee”). Recitals A. For purposes of this Agreement

May 27, 2025 EX-99.1

Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media  Investors Heather Zoumas-Lubeski David DeMartino 445-248-0577 646-531-6115 [email protected] [email protected] Zach Weiner 908-591-6955 [email protected] Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas (WARSAW, IN) May 27, 2025 — Zimme

May 27, 2025 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissi

May 27, 2025 EX-10.1

Offer Letter, dated as of May 20, 2025, by and between Zimmer Biomet Holdings, Inc. and Kevin Thornal.

Exhibit 10.1 Confidential May 20, 2025 Kevin Thornal [***] [***] Dear Kevin, We are pleased to offer you the position of Group President, Global Businesses and the Americas reporting to me. You will be paid a gross annual salary of $850,000 in bi-weekly installments and your salary grade will be a Z02. Your position is exempt, as such, your annual salary is intended to compensate you for all hours

May 23, 2025 EX-1.01

Conflict Minerals Report of Zimmer Biomet Holdings, Inc.

Exhibit 1.01 ZIMMER BIOMET HOLDINGS, INC. Conflict Minerals Report For the Reporting Period from January 1, 2024 to December 31, 2024 This Conflict Minerals Report (this “Report”) of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet,” the “Company,” “we,” “our” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (collectively, the “Rule”) promulgated under the Securities Exchange Act of 1934,

May 23, 2025 SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 345 East Main Street Warsaw, Indiana 46580 (Address of principal ex

May 5, 2025 EX-10.1

Swiss Employment Agreement by and between Zimmer GmbH and Jehanzeb Noor dated as of February 13, 2025

Exhibit 10.1 Zimmer GmbH Zählerweg 4 CH-6300 Zug Phone +41 (0)58 854 90 00 www.zimmerbiomet.com Employment Agreement between Zimmer GmbH Zählerweg 4, 6300 Zug (hereinafter referred to as "Zimmer") and Mr. Jehanzeb Noor, born on January 7, 1982, American Citizen (hereinafter referred as "Mr. Noor“) will be hired in terms of Art. 319ff. CO ("Agreement"). 1. Hire date, position and work location 1.1

May 5, 2025 EX-10.3

Confidentiality, Non-Competition and Non-Solicitation Agreement dated as of February 14, 2025 by and between Zimmer GmbH and Jehanzeb Noor

Exhibit 10.3 Zimmer GmbH Zählerweg 4 CH-6300 Zug Phone +41 (0)58 854 90 00 www.zimmerbiomet.com Confidentiality, Non-Competition, and Non-Solicitation Agreement between Zimmer GmbH Zählerweg 4, 6300 Zug („Employer“) and Mr. Jehanzeb Noor („Employee“) (collectively the "Parties") Recitals (A) For purposes of this Agreement, "Parent" means an entity which is a holding company of or holds a controlli

May 5, 2025 EX-99.1

Zimmer Biomet Announces First Quarter 2025 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 [email protected] [email protected] Zach Weiner (908) 591-6955 [email protected] Zimmer Biomet Announces First Quarter 2025 Financial Results • First quarter net sales of $1.909 billion increased 1.1%

May 5, 2025 10-Q

SECURITIES AND EXCHANGE COMMISSION FOR THE QUARTERLY PERIOD ENDED March 31, 2025 March 31, 2025 Page Part I - Financial Information Part II - Other Information Signatures 37 1. Basis of Presentation 2. Significant Accounting Polici

` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2025 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation

May 5, 2025 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissio

May 5, 2025 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of March 31, 2025 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International, Inc. Delaware Biomet Manufacturing, LLC In

May 5, 2025 EX-10.2

Change in Control Severance Agreement by and between Zimmer GmbH and Jehanzeb Noor effective as of February 13, 2025

Exhibit 10.2 Change in Control Severance Agreement This Change in Control Severance Agreement ("Agreement") is made by and between Zimmer GmbH ("Employer" or "Company" as case may be) and Jehanzeb Noor ("Executive"). Recitals (A) The Company considers it essential to the best interests of its ultimate shareholders to foster the continuous employment of key management personnel. (B) The Company and

April 21, 2025 EX-99.1

Zimmer Biomet Completes Acquisition of Paragon 28 Transaction Further Strengthens Company’s Position in High-Growth Foot and Ankle Segment

Exhibit 99.1 Zimmer Biomet: Media Heather Zoumas-Lubeski 445-248-0577 [email protected] Kirsten Fallon 781-779-5562 [email protected] Investors David DeMartino 646-531-6115 [email protected] Zach Weiner 908-591-6955 [email protected] Zimmer Biomet Completes Acquisition of Paragon 28 Transaction Further Strengthens Company’s Position in

April 21, 2025 8-K

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis

April 14, 2025 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

April 14, 2025 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin

April 2, 2025 PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☑ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

February 25, 2025 EX-99.1

 345 E. Main St.  Warsaw, IN 46580  www.zimmerbiomet.com Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 [email protected] [email protected] Zach Weiner (908) 591-6955 zach.wein

Exhibit 99.1  345 E. Main St.  Warsaw, IN 46580  www.zimmerbiomet.com Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 [email protected] [email protected] Zach Weiner (908) 591-6955 [email protected] Zimmer Biomet Announces Upcoming Changes to Company’s Board of Directors (WARSAW, IN) February 25, 2025 — Zimmer Biom

February 25, 2025 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2024 Commission file number 001-16407 ZIMMER BIOMET HOL

I have UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2024 Commission file number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State of Incorporation) (IRS Employer Identification No

February 25, 2025 EX-FILING FEES

Calculation of Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC.

February 25, 2025 EX-25.1

Statement of Eligibility of Computershare Trust Company, N.A. on Form T-1 for Debt Securities.

Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) N

February 25, 2025 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of December 31, 2024 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International, Inc. Delaware Biomet Manufacturing, LLC

February 25, 2025 8-K

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com

February 25, 2025 S-3ASR

As filed with the Securities and Exchange Commission on February 25, 2025

Table of Contents As filed with the Securities and Exchange Commission on February 25, 2025 Registration No.

February 25, 2025 EX-19

Zimmer Biomet Holdings, Inc. Stock Trading Policy, effective April 26, 2023

LEGAL 101 Rev. 3 Global Policy STOCK TRADING POLICY Level 1 Non-QMS Document Effective Date: 26 APR 2023 Exhibit 19 PURPOSE Securities laws prohibit individuals from trading in the securities of a company while they are aware of material information about that company that is not generally known or available to the public. Such trading is often referred to as “insider trading.” The purpose of this

February 25, 2025 EX-4.1

Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934

Exhibit 4.1 Description of the Registrant’s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2024, Zimmer Biomet Holdings, Inc. (the “Company,” “we,” “our” and “us” refer solely to Zimmer Biomet Holdings, Inc.) maintained four classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1

February 19, 2025 8-K

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com

February 19, 2025 EX-4.2

Twelfth Supplemental Indenture, dated as of February 19, 2025, between Zimmer Biomet Holdings, Inc. and Computershare Trust Company, N.A., as trustee.

EX-4.2 Exhibit 4.2 ZIMMER BIOMET HOLDINGS, INC. $600,000,000 4.700% Notes due 2027 $550,000,000 5.050% Notes due 2030 $600,000,000 5.500% Notes due 2035 TWELFTH SUPPLEMENTAL INDENTURE Dated as of February 19, 2025 to Indenture dated as of November 17, 2009 COMPUTERSHARE TRUST COMPANY, N.A. Trustee Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Application

February 18, 2025 8-K

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com

February 18, 2025 EX-1.1

Underwriting Agreement, dated as of February 11, 2025, among Zimmer Biomet Holdings, Inc., Goldman Sachs & Co. LLC, Barclays Capital Inc., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and SMBC Nikko Securities America, Inc., as representatives of the several underwriters named in Schedule I thereto.

Exhibit 1.1 Execution Version Zimmer Biomet Holdings, Inc. $600,000,000 4.700% Notes due 2027 $550,000,000 5.050% Notes due 2030 $600,000,000 5.500% Notes due 2035 Underwriting Agreement New York, New York February 11, 2025 Goldman Sachs & Co. LLC Barclays Capital Inc. Citigroup Global Markets Inc. Morgan Stanley & Co. LLC SMBC Nikko Securities America, Inc. As representatives of the several under

February 13, 2025 EX-FILING FEES

Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC.

February 13, 2025 424B5

$1,750,000,000 Zimmer Biomet Holdings, Inc. $600,000,000 4.700% Notes due 2027 $550,000,000 5.050% Notes due 2030 $600,000,000 5.500% Notes due 2035

As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 PROSPECTUS SUPPLEMENT (To Prospectus dated February 25, 2022) $1,750,000,000 Zimmer Biomet Holdings, Inc. $600,000,000 4.700% Notes due 2027 $550,000,000 5.050% Notes due 2030 $600,000,000 5.500% Notes due 2035 We are offering for sale $600,000,000 aggregate principal amount of 4.700% notes due 2027 (the “2027 notes”), $550,

February 11, 2025 424B5

SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED FEBRUARY 11, 2025

Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 The information in this preliminary prospectus supplement is not complete and may be changed. An effective registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer t

February 11, 2025 FWP

Zimmer Biomet Holdings, Inc. Pricing Term Sheet $600,000,000 4.700% Notes due 2027 $550,000,000 5.050% Notes due 2030 $600,000,000 5.500% Notes due 2035 February 11, 2025

Filed Pursuant to Rule 433 under the Securities Act of 1933, as amended Registration Statement No.

February 6, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm

February 6, 2025 EX-99.1

Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 [email protected] [email protected] Zach Weiner (908) 591-6955 [email protected] Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results • Fourth quarter net sales of $2.023 billion

January 29, 2025 EX-99.2

Disclaimer Cautionary Note Regarding Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including any statements

Exhibit 99.2 ZIMMER BIOMET MOVING YOU MOVING YOU F FO OR RW WA AR RD D ZBH Acquisition of Paragon 28 2024 Investor Day January 28, 2025 Disclaimer Cautionary Note Regarding Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including any statements about us; Para

January 29, 2025 EX-99.1

Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 Demonstrates Zimmer Biomet’s Commitment to Investing in Higher Growth End-Markets, with Expansion into ~$5 Billion Foot and Ankle Segment Expected to Enhance Zimmer Biomet’s Financial

Exhibit 99.1 Zimmer Biomet: Media Investors Heather Zoumas-Lubeski 445-248-0577 [email protected] Kirsten Fallon 781-779-5562 [email protected] David DeMartino 646-531-6115 [email protected] Zach Weiner 908-591-6955 [email protected] Paragon 28: Media and Investors: Matt Brinckman 720-912-1332 [email protected] Zimmer Biomet Annou

January 29, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm

January 29, 2025 DFAN14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm

January 29, 2025 DFAN14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm

January 29, 2025 EX-99.1

VOTING AGREEMENT

Exhibit 99.1 Execution Version VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of January 28, 2025, is by and among Zimmer, Inc., a Delaware corporation (“Parent”), Gazelle Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and each of the undersigned stockholders (each, a “Stockholder”, and together the “Stockholders”) of the Com

January 29, 2025 EX-2.1

Agreement and Plan of Merger, dated as of January 28, 2025, by and among Zimmer, Inc., Gazelle Merger Sub I, Inc., Paragon 28, Inc. and Zimmer Biomet Holdings, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed January 29, 2025)

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER By and Among ZIMMER, INC., GAZELLE MERGER SUB I, INC., PARAGON 28, INC. and, solely for purposes of Section 8.15, ZIMMER BIOMET HOLDINGS, INC. Dated as of January 28, 2025 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.01. The Merger 2 Section 1.02. Merger Closing 2 Section 1.03. Effective Time 3 Section 1.04. Effects of the Merge

January 29, 2025 8-K

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm

November 20, 2024 EX-4.2

Eleventh Supplemental Indenture, dated as of November 20, 2024, between Zimmer Biomet Holdings, Inc. and Computershare Trust Company, N.A., as trustee.

EX-4.2 Exhibit 4.2 Execution Version ZIMMER BIOMET HOLDINGS, INC. €700,000,000 3.518% Notes due 2032 ELEVENTH SUPPLEMENTAL INDENTURE Dated as of November 20, 2024 to Indenture dated as of November 17, 2009 COMPUTERSHARE TRUST COMPANY, N.A. Trustee Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Application of this Eleventh Supplemental Indenture 1 SECTION

November 20, 2024 8-A12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Reg

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ZIMMER BIOMET HOLDINGS, INC.

November 20, 2024 EX-4.3

Agency Agreement, dated as of November 20, 2024, by and among Zimmer Biomet Holdings, Inc., as issuer, U.S. Bank Europe DAC, UK Branch, as paying agent, U.S. Bank Trust Company, National Association, as registrar and transfer agent, and Computershare Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed November 20, 2024).

EX-4.3 Exhibit 4.3 DATED NOVEMBER 20, 2024 ZIMMER BIOMET HOLDINGS, INC., AS ISSUER U.S. BANK EUROPE DAC, UK BRANCH, AS PAYING AGENT U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS TRANSFER AGENT U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS REGISTRAR - AND - COMPUTERSHARE TRUST COMPANY, N.A., AS TRUSTEE AGENCY AGREEMENT relating to Notes issued pursuant to a registration statement including

November 20, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 ZIMMER BIOMET H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com

November 19, 2024 EX-1.1

Underwriting Agreement, dated as of November 13, 2024, among Zimmer Biomet Holdings, Inc., Barclays Bank PLC, Goldman Sachs & Co. LLC, HSBC Bank plc and RBC Europe Limited.

Exhibit 1.1 Execution Version Zimmer Biomet Holdings, Inc. €700,000,000 3.518% Notes due 2032 Underwriting Agreement New York, New York November 13, 2024 Barclays Bank PLC Goldman Sachs & Co. LLC HSBC Bank plc RBC Europe Limited As representatives of the several underwriters named in Schedule I hereto c/o Barclays Bank PLC 1 Churchill Place London, E14 5HP United Kingdom Goldman Sachs & Co. LLC 20

November 19, 2024 8-K

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com

November 14, 2024 424B5

€700,000,000 Zimmer Biomet Holdings, Inc. 3.518% Notes due 2032

As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 PROSPECTUS SUPPLEMENT (To Prospectus dated February 25, 2022)   €700,000,000 Zimmer Biomet Holdings, Inc. 3.518% Notes due 2032 We are offering for sale €700,000,000 aggregate principal amount of 3.518% notes due 2032 (the “notes”). We will pay interest on the notes annually in arrears on December 15 of each year, commencing

November 14, 2024 EX-FILING FEES

Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC.

November 13, 2024 SC 13G/A

ZBH / Zimmer Biomet Holdings, Inc. / DODGE & COX - SC 13G/A Passive Investment

SC 13G/A 1 d812440dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* ZIMMER BIOMET HOLDINGS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 98956P102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

November 13, 2024 FWP

Zimmer Biomet Holdings, Inc. Pricing Term Sheet €700,000,000 3.518% Notes due 2032 November 13, 2024

Filed Pursuant to Rule 433 under the Securities Act of 1933, as amended Registration Statement No.

November 13, 2024 424B5

SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED NOVEMBER 13, 2024

Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 The information in this preliminary prospectus supplement is not complete and may be changed. An effective registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer t

October 30, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm

October 30, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024 Commission File Number 001-164

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporati

October 30, 2024 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of September 30, 2024 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet Internatio

October 30, 2024 EX-99.1

Zimmer Biomet Announces Third Quarter 2024 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 [email protected] [email protected] Zach Weiner (908) 591-6955 [email protected] Zimmer Biomet Announces Third Quarter 2024 Financial Results • Third quarter net sales of $1.824 billion increased 4.0%

August 15, 2024 8-K

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commi

August 15, 2024 EX-4.2

Tenth Supplemental Indenture, dated as of August 15, 2024, between Zimmer Biomet Holdings, Inc. and Computershare Trust Company, N.A., as trustee.

Exhibit 4.2 ZIMMER BIOMET HOLDINGS, INC. $700,000,000 5.200% Notes due 2034 TENTH SUPPLEMENTAL INDENTURE Dated as of August 15, 2024 to Indenture dated as of November 17, 2009 COMPUTERSHARE TRUST COMPANY, N.A. Trustee    Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Application of this Tenth Supplemental Indenture 1 SECTION 1.02. Definitions 2 SECTION 1.

August 14, 2024 EX-1.1

Underwriting Agreement, dated as of August 8, 2024, among Zimmer Biomet Holdings, Inc., Barclays Capital Inc., BNP Paribas Securities Corp., BofA Securities, Inc., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC.

Exhibit 1.1 [Execution] Zimmer Biomet Holdings, Inc. $700,000,000 5.200% Notes due 2034 Underwriting Agreement New York, New York August 8, 2024 Barclays Capital Inc. BNP Paribas Securities Corp. BofA Securities, Inc. Citigroup Global Markets Inc. J.P. Morgan Securities LLC As representatives of the several underwriters named in Schedule I hereto c/o Barclays Capital Inc. 745 Seventh Avenue New Yo

August 14, 2024 8-K

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis

August 9, 2024 FWP

Zimmer Biomet Holdings, Inc. Pricing Term Sheet $700,000,000 5.200% Notes due 2034 August 8, 2024

Filed Pursuant to Rule 433 under the Securities Act of 1933, as amended Registration Statement No.

August 9, 2024 424B5

$700,000,000 Zimmer Biomet Holdings, Inc. 5.200% Notes due 2034

Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 PROSPECTUS SUPPLEMENT (To Prospectus dated February 25, 2022) $700,000,000 Zimmer Biomet Holdings, Inc. 5.200% Notes due 2034 We are offering for sale $700,000,000 aggregate principal amount of 5.200% notes due 2034 (the “notes”). We will pay interest on the notes on March 15 and September 15 of each year,

August 9, 2024 EX-FILING FEES

Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC.

August 8, 2024 424B5

SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED AUGUST 8, 2024

424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No.

August 7, 2024 8-K

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis

August 7, 2024 EX-99.1

EXPLANATORY NOTE

Exhibit 99.1 EXPLANATORY NOTE Zimmer Biomet Holdings, Inc. (“we”, “us”, “our”, the “Company” and other similar words) is filing this Exhibit 99.1 to its Current Report on Form 8-K (including this Exhibit 99.1, the “Form 8-K”) solely to recast certain financial information and related disclosures included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, origi

August 7, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis

August 7, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2024 Commission File Number 001-16407 ZI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2024 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or

August 7, 2024 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of June 30, 2024 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International,

August 7, 2024 EX-99.1

Zimmer Biomet Announces Second Quarter 2024 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces Second Quarter 2024 Financial Results • Second quarter net sales of $1.942 billion increased 3.9% and 5.6% on a constant currency1 basis • Second quarter dilute

July 1, 2024 EX-10.2

364-Day Revolving Credit Agreement, dated as of June 28, 2024, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

Exhibit 10.2 EXECUTION VERSION 364-DAY REVOLVING CREDIT AGREEMENT dated as of June 28, 2024, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURITIE

July 1, 2024 EX-10.1

Five-Year Revolving Credit Agreement, dated as of June 28, 2024, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

Exhibit 10.1 EXECUTION VERSION FIVE-YEAR REVOLVING CREDIT AGREEMENT dated as of June 28, 2024, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURIT

July 1, 2024 8-K

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commiss

June 20, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commiss

June 20, 2024 EX-99.1

Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors (WARSAW, IN) June 20, 2024 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology

June 5, 2024 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Zimmer Biomet Holdings, Inc.

June 5, 2024 S-8

As filed with the Securities and Exchange Commission on June 5, 2024

As filed with the Securities and Exchange Commission on June 5, 2024 Registration No.

May 22, 2024 SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 (State or other jurisdiction of incorporation) (Commission File Number) 345 East Main Street Warsaw, Indiana 46580 (Address of principal executive offices) (Zip Code) Chad F. Phipps Senio

May 22, 2024 EX-1.01

Conflict Minerals Report of Zimmer Biomet Holdings, Inc.

Exhibit 1.01 ZIMMER BIOMET HOLDINGS, INC. Conflict Minerals Report For the Reporting Period from January 1, 2023 to December 31, 2023 This Conflict Minerals Report (this “Report”) of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet,” the “Company,” “we,” “our” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (collectively, the “Rule”) promulgated under the Securities Exchange Act of 1934,

May 15, 2024 EX-10.1

Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan, as amended and restated effective May 10, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed May 15, 2024)

Exhibit 10.1 ZIMMER BIOMET HOLDINGS, INC. EMPLOYEE STOCK PURCHASE PLAN (As amended and restated effective May 10, 2024) Section 1. Designation and Purpose. The name of this Plan is the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company.

May 15, 2024 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissi

May 2, 2024 EX-99.1

Zimmer Biomet Announces First Quarter 2024 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces First Quarter 2024 Financial Results • First quarter net sales of $1.889 billion increased 3.2% and 4.4% on a constant currency1 basis • First quarter diluted e

May 2, 2024 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of March 31, 2024 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International,

May 2, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissio

May 2, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2024 Commission File Number 001-16407 Z

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2024 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation o

March 27, 2024 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

March 27, 2024 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin

February 23, 2024 EX-10.52

Amendment to Change in Control Severance Agreement dated February 19, 2024 between Zimmer GmbH and Wilfred van Zuilen

Exhibit 10.52 Amendment to Change in Control Severance Agreement Recitals (A) On 5 May 2021, Zimmer GmbH ("Employer" or "Company" as case may be) and Wilfred van Zuilen ("Executive"; the Employer and the Executive each individually, a "Party" and together, the "Parties") have entered into a Change in Control Severance Agreement ("CIC Agreement"). (B) The Parties know wish to amend the CIC Agreemen

February 23, 2024 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2023 Commission file number 001-16407 ZIMMER BIOMET HOL

I have UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2023 Commission file number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State of Incorporation) (IRS Employer Identification No

February 23, 2024 EX-97.1

Zimmer Biomet Holdings, Inc. Compensation Recovery Policy, effective October 2, 2023

Exhibit 97.1 ZIMMER BIOMET HOLDINGS, INC. COMPENSATION RECOVERY POLICY Policy The Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”) has adopted this Compensation Recovery Policy (this “Policy”) pursuant to Rule 10D-1 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”),

February 23, 2024 EX-10.51

Form of Amendment to Change in Control Severance Agreement with Ivan Tornos, Suketu Upadhyay, Rachel Ellingson, Lori Winkler and Paul Stellato

Exhibit 10.51 AMENDMENT TO CHANGE IN CONTROL SEVERANCE AGREEMENT This Amendment to Change in Control Severance Agreement (this “Amendment”) is made by and between ZIMMER BIOMET HOLDINGS, INC., a Delaware corporation (the “Company”) and (the “Executive”), as of (the “Effective Date”). The Company and Executive are hereinafter collectively referred to as the “Parties.” Recitals A. The Company and th

February 23, 2024 EX-10.53

Deed of Amendment dated February 19, 2024 between Zimmer Asia (HK) Limited and Sang-Uk Yi

Exhibit 10.53 Deed of Amendment This Deed is made on February 19, 2024 Between: (1) Zimmer Asia (HK) Limited, a company incorporated in Hong Kong (registered number 52194097) (the "Company"); and (2) Yi Sang-Uk (the “Executive”). Background: (A) The Company and the Executive have entered into a Change in Control Severance Agreement on June 15, 2020 (the "Agreement"). (B) The Company and the Execut

February 23, 2024 EX-10.54

Form of Change in Control Severance Agreement with Kevin Thornal (incorporated by reference to Exhibit 10.54 to the Registrant’s Annual Report on Form 10-K filed February 23, 2024)

Exhibit 10.54 CHANGE IN CONTROL SEVERANCE AGREEMENT THIS AGREEMENT, dated as of , is made by and between ZIMMER BIOMET HOLDINGS, INC., a Delaware corporation (the “Company”), and (the “Executive”). The capitalized words and terms used throughout this Agreement are defined in Article XIII. Recitals A. The Company considers it essential to the best interests of its stockholders to foster the continu

February 23, 2024 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of December 31, 2023 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet Internation

February 13, 2024 SC 13G/A

ZBH / Zimmer Biomet Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02333-zimmerbiometholdings.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Zimmer Biomet Holdings Inc Title of Class of Securities: Common Stock CUSIP Number: 98956P102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box

February 13, 2024 SC 13G

ZBH / Zimmer Biomet Holdings, Inc. / DODGE & COX - SC 13G Passive Investment

SC 13G 1 d719732dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 0 )* ZIMMER BIOMET HOLDINGS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 98956P102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

February 8, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm

February 8, 2024 EX-99.1

Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results • Fourth quarter net sales of $1.940 billion increased 6.3% and 6.1% on a constant currency1 basis • Fourth

January 5, 2024 EX-99.1

Zimmer Biomet Announces Appointment of Louis A. Shapiro to Board of Directors

EX-99.1 Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces Appointment of Louis A. Shapiro to Board of Directors (WARSAW, IN) January 5, 2024 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical

January 5, 2024 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Employe

December 1, 2023 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com

December 1, 2023 EX-4.2

Ninth Supplemental Indenture, dated as of December 1, 2023, between Zimmer Biomet Holdings, Inc. and Computershare Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed December 1, 2023)

EXHIBIT 4.2 [Execution] ZIMMER BIOMET HOLDINGS, INC. $500,000,000 5.350% Notes due 2028 NINTH SUPPLEMENTAL INDENTURE Dated as of December 1, 2023 to Indenture dated as of November 17, 2009 COMPUTERSHARE TRUST COMPANY, N.A. Trustee Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Application of this Ninth Supplemental Indenture 1 SECTION 1.02. Definitions 2

December 1, 2023 EX-1.1

Underwriting Agreement, dated as of November 28, 2023, among Zimmer Biomet Holdings, Inc., Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC.

EXHIBIT 1.1 [Execution] Zimmer Biomet Holdings, Inc. $500,000,000 5.350% Notes due 2028 Underwriting Agreement New York, New York November 28, 2023 Barclays Capital Inc. Goldman Sachs & Co. LLC Mizuho Securities USA LLC Morgan Stanley & Co. LLC As representatives of the several underwriters named in Schedule I hereto c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 Goldman Sac

November 30, 2023 EX-FILING FEES

Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amo

Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC.

November 30, 2023 424B5

$500,000,000 Zimmer Biomet Holdings, Inc. 5.350% Notes due 2028

Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 PROSPECTUS SUPPLEMENT (To Prospectus dated February 25, 2022) $500,000,000 Zimmer Biomet Holdings, Inc. 5.350% Notes due 2028 We are offering for sale $500,000,000 aggregate principal amount of 5.350% notes due 2028 (the “notes”). We will pay interest on the notes on June 1 and December 1 of each year, comm

November 28, 2023 424B5

SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED NOVEMBER 28, 2023

Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 The information in this preliminary prospectus supplement is not complete and may be changed. An effective registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer t

November 28, 2023 FWP

Zimmer Biomet Holdings, Inc. Pricing Term Sheet $500,000,000 5.350% Notes due 2028 November 28, 2023

Filed Pursuant to Rule 433 under the Securities Act of 1933, as amended Registration Statement No.

November 7, 2023 EX-10.6

Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors, as amended August 25, 2023 (incorporated by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q filed November 7, 2023)

Exhibit 10.6 ZIMMER BIOMET HOLDINGS, INC. DEFERRED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS (As Amended on August 25, 2023) Section 1. Eligibility. Any member of the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”) who is not an officer or employee of the Company or a subsidiary thereof is eligible to participate in the Plan and will be a participant. Section 2.

November 7, 2023 EX-99.1

Zimmer Biomet Announces Third Quarter 2023 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Zach Weiner (703) 346-3127 (908) 591-6955 [email protected] [email protected] Heather Zoumas-Lubeski (445) 248-0577 [email protected] Zimmer Biomet Announces Third Quarter 2023 Financial Results • Third quarter net sales of $1.754 billion increased 5

November 7, 2023 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of September 30, 2023 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Armada Merger Corp. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International, I

November 7, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm

November 7, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 Commission File Number 001-164

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporati

August 22, 2023 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Employe

August 22, 2023 EX-10.1

Offer Letter, dated as of August 21, 2023, by and between Zimmer Biomet Holdings, Inc. and Ivan Tornos (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed August 22, 2023)

Exhibit 10.1 Confidential August 21, 2023 Ivan Tornos Dear Ivan, We are pleased to offer you the role of President and Chief Executive Officer (CEO) of Zimmer Biomet Holdings, Inc. (the Company or Zimmer Biomet). You will report directly to the Company’s Board of Directors. Your salary grade will be level Z01. Your start date as President and CEO will be Tuesday, August 22, 2023 (the “Effective Da

August 22, 2023 EX-99.1

Zimmer Biomet Announces Leadership Transition Chief Operating Officer Ivan Tornos Appointed President and CEO; Elected to the Board of Directors Chief Financial Officer Suketu (Suky) Upadhyay’s Role Expands to CFO and EVP, Finance, Operations & Suppl

Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Heather Zoumas-Lubeski (445) 248-0577 [email protected] Zach Weiner (908) 591-6955 [email protected] Zimmer Biomet Announces Leadership Transition Chief Operatin

August 22, 2023 EX-10.2

Change in Control Severance Agreement, dated as of August 21, 2023, by and between Zimmer Biomet Holdings, Inc. and Ivan Tornos (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed August 22, 2023)

Exhibit 10.2 CHANGE IN CONTROL SEVERANCE AGREEMENT THIS AGREEMENT, dated as of August 21, 2023, is made by and between ZIMMER BIOMET HOLDINGS, INC., a Delaware corporation (the “Company”), and Ivan Tornos (the “Executive”). The capitalized words and terms used throughout this Agreement are defined in Article XIII. Recitals A. The Company considers it essential to the best interests of its stockhol

August 22, 2023 EX-10.3

Chief Executive Officer Confidentiality, Non-Competition and Non-Solicitation Agreement, dated as of August 21, 2023, by and between Zimmer Biomet Holdings, Inc. and Ivan Tornos (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K filed August 22, 2023)

Exhibit 10.3 CHIEF EXECUTIVE OFFICER CONFIDENTIALITY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT This Chief Executive Officer Confidentiality, Non-Competition and Non-Solicitation Agreement (“Agreement”) is made by and between Zimmer Biomet Holdings, Inc., a corporation having its principal headquarters in Warsaw, Indiana, and Ivan Tornos (“Executive”). Recitals A. For purposes of this Agreeme

August 1, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 Commission File Number 001-16407 ZI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or

August 1, 2023 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of June 30, 2023 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International, Inc. Delaware Biomet Leasing, Inc.

August 1, 2023 EX-99.1

Zimmer Biomet Announces Second Quarter 2023 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Zach Weiner (703) 346-3127 (908) 591-6955 [email protected] [email protected] Heather Zoumas-Lubeski (445) 248-0577 [email protected] Zimmer Biomet Announces Second Quarter 2023 Financial Results • Second quarter net sales of $1.870 billion increased

August 1, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis

July 10, 2023 8-K

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commissi

July 10, 2023 EX-10.2

364-Day Revolving Credit Agreement, dated as of July 7, 2023, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

EX-10.2 Exhibit 10.2 EXECUTION VERSION 364-DAY REVOLVING CREDIT AGREEMENT dated as of July 7, 2023, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SE

July 10, 2023 EX-10.1

Five-Year Revolving Credit Agreement, dated as of July 7, 2023, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

EX-10.1 Exhibit 10.1 EXECUTION VERSION FIVE-YEAR REVOLVING CREDIT AGREEMENT dated as of July 7, 2023, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC

June 16, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 ZIMMER BIOMET HOLDI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commiss

June 16, 2023 424B5

107,822 Shares Zimmer Biomet Holdings, Inc. Common Stock

424B5 Table of Contents As filed pursuant to Rule 424(b)(5) Registration Statement No.

June 16, 2023 EX-FILING FEES

Calculation of Filing Fee Tables (Form Type) Zimmer Biomet Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Propos

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Zimmer Biomet Holdings, Inc.

May 19, 2023 SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 (State or other jurisdiction of incor

SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 (State or other jurisdiction of incorporation) (Commission File Number) 345 East Main Street Warsaw, Indiana 46580 (Address of principal executive offices) (Zip Code) Chad F. Phipps Se

May 19, 2023 SC 13G/A

ZIMV / ZimVie Inc / ZIMMER BIOMET HOLDINGS, INC. - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ZimVie Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98888T107 (CUSIP Number) February 1, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil

May 19, 2023 EX-1.01

Conflict Minerals Report of Zimmer Biomet Holdings, Inc.

Exhibit 1.01 ZIMMER BIOMET HOLDINGS, INC. Conflict Minerals Report For the Reporting Period from January 1, 2022 to December 31, 2022 This Conflict Minerals Report (this “Report”) of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet,” the “Company,” “we,” “our” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (collectively, the “Rule”) promulgated under the Securities Exchange Act of 1934,

May 16, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 ZIMMER BIOMET HOLDIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Employer o

May 2, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissio

May 2, 2023 EX-99

Zimmer Biomet Announces First Quarter 2023 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces First Quarter 2023 Financial Results

May 2, 2023 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of March 31, 2023 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International Orthopedics, LLC Delaware Biomet In

May 2, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 Commission File Number 001-16407 Z

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation o

March 30, 2023 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant t o Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant t o Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 1

March 30, 2023 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registr

DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

March 30, 2023 DEF 14A

PDF OF DEFINITIVE PROXY STATEMENT

Notice of 2023 Annual Meeting of Shareholders and Proxy Statement Friday, May 12, 2023 8 a.

February 24, 2023 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of December 31, 2022 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Bayeux Acquisition Corp. Virginia Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet Internationa

February 24, 2023 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2022 Commission file number 001-16407 ZIMMER BIOMET HOL

I have UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2022 Commission file number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State of Incorporation) (IRS Employer Identification No

February 24, 2023 EX-3

Restated Bylaws of Zimmer Biomet Holdings, Inc., effective December 14, 2022 (incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K filed February 24, 2023)

Exhibit 3.2 RESTATED BYLAWS OF ZIMMER BIOMET HOLDINGS, INC. (hereinafter called the “Corporation”) Effective: December 14, 2022 ARTICLE I Offices and Records SECTION 1.01. Registered Office. The registered office of the Corporation in the State of Delaware is located at 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808, and the registered agent at such address is Cor

February 24, 2023 EX-4

Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934

Exhibit 4.1 Description of the Registrant’s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2022, Zimmer Biomet Holdings, Inc. (the “Company,” “we,” “our” and “us” refer solely to Zimmer Biomet Holdings, Inc.) maintained three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (

February 15, 2023 EX-FILING FEES

Calculation of Filing Fee Tables (Form Type) Zimmer Biomet Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Propos

EX-FILING FEES 2 d460473dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Zimmer Biomet Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price

February 15, 2023 8-K

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Com

February 15, 2023 424B5

1,059,992 Shares Zimmer Biomet Holdings, Inc. Common Stock

424B5 1 d460473d424b5.htm 424B5 Table of Contents As filed pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 PROSPECTUS SUPPLEMENT (To Prospectus dated February 25, 2022) 1,059,992 Shares Zimmer Biomet Holdings, Inc. Common Stock This prospectus supplement relates to the offering and resale by the selling stockholders identified herein of up to 1,059,992 shares (the “offered shares”

February 9, 2023 SC 13G/A

ZBH / Zimmer Biomet Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02299-zimmerbiometholdings.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Zimmer Biomet Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 98956P102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate bo

February 3, 2023 EX-99.1

Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Heather Zoumas-Lubeski (445) 248-0577 [email protected] Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results • Fourth quarter net sales from continui

February 3, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm

January 27, 2023 SC 13G

ZIMV / ZimVie Inc / ZIMMER BIOMET HOLDINGS, INC. - SC 13G Passive Investment

SC 13G 1 d447736dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ZimVie Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98888T107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

December 14, 2022 EX-3.1

Restated Bylaws of Zimmer Biomet Holdings, Inc., effective December 14, 2022

Exhibit 3.1 RESTATED BYLAWS OF ZIMMER BIOMET HOLDINGS, INC. (hereinafter called the ?Corporation?) Effective: May 17, 2021 December 14, 2022 ARTICLE I Offices and Records SECTION 1.01. Registered Office. The registered office of the Corporation in the State of Delaware is located at 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808, and the registered agent at such a

December 14, 2022 8-K

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Emplo

December 13, 2022 EX-99.25

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 27, 2022, pursuant to the provisions of Rule 12d2-2 (a).

November 7, 2022 SC 13G/A

ZBH / Zimmer Biomet Holdings Inc / JPMORGAN CHASE & CO - FILING ZIMMER BIOMET HOLDINGS, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* ZIMMER BIOMET HOLDINGS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 98956P102 (CUSIP Number) October 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

November 2, 2022 EX-99.1

Zimmer Biomet Announces Third Quarter 2022 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Heather Zoumas-Lubeski (445) 248-0577 [email protected] Zimmer Biomet Announces Third Quarter 2022 Financial Results • Third quarter net sales from continuing operations of

November 2, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2022 Commission File Number 001-164

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2022 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporati

November 2, 2022 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of September 30, 2022 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International Orthopedics, LLC Delaware Biome

November 2, 2022 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm

August 22, 2022 EX-10.2

364-Day Revolving Credit Agreement, dated as of August 19, 2022, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

EXHIBIT 10.2 364-DAY REVOLVING CREDIT AGREEMENT dated as of August 19, 2022, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., CITIBANK, N.A., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURITIES (USA) INC., MIZUHO BANK, LTD., MO

August 22, 2022 EX-10.1

Five-Year Revolving Credit Agreement, dated as of August 19, 2022, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

EXHIBIT 10.1 FIVE-YEAR REVOLVING CREDIT AGREEMENT dated as of August 19, 2022, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., CITIBANK, N.A., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURITIES (USA) INC., MIZUHO BANK, LTD.,

August 22, 2022 8-K

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commi

August 2, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 Commission File Number 001-16407 ZI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or

August 2, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commi

August 2, 2022 EX-99.1

Zimmer Biomet Announces Second Quarter 2022 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Second Quarter 2022 Financial Results ? Second quarter net sales from continuing operations of $1.782 billion incre

August 2, 2022 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of June 30, 2022 Name of Subsidiary Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International Orthopedics, LLC Delaware Biomet Inte

June 22, 2022 8-K

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commiss

June 22, 2022 EX-99.1

EXPLANATORY NOTE

Exhibit 99.1 EXPLANATORY NOTE Zimmer Biomet Holdings, Inc. (?we?, ?us?, ?our?, the ?Company? and other similar words) is filing this Exhibit 99.1 to its Current Report on Form 8-K (including this Exhibit 99.1, the ?Form 8-K?) solely to recast certain financial information and related disclosures included in the Company?s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, origi

May 23, 2022 EX-1.01

Conflict Minerals Report of Zimmer Biomet Holdings, Inc.

EX-1.01 2 d291956dex101.htm EX-1.01 Exhibit 1.01 ZIMMER BIOMET HOLDINGS, INC. Conflict Minerals Report For the Reporting Period from January 1, 2021 to December 31, 2021 This Conflict Minerals Report (this “Report”) of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet,” the “Company,” “we,” “our” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (collectively, the “Rule”) promulgated under

May 23, 2022 SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 (State or other jurisdiction of incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 (State or other jurisdiction of incorporation) (Commission File Number) 345 East Main Street Warsaw, Indiana 46580 (Address of principal executive offices) (Zip Code) Chad F. Phipps Senio

May 19, 2022 8-K

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commissi

May 16, 2022 EX-99.1

Zimmer Biomet Announces Appointment of New Chief Accounting Officer Paul Stellato Joins Zimmer Biomet as Vice President, Controller and Chief Accounting Officer

Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox 703-346-3127 215-275-2431 [email protected] [email protected] Ezgi Yagci 617-549-2443 [email protected] Zimmer Biomet Announces Appointment of New Chief Accounting Officer Paul Stellato Joins Zimmer Biomet as Vice President, Controller and Chief Acc

May 16, 2022 EX-10.1

Offer Letter by and between Zimmer Biomet Holdings, Inc. and Paul Stellato dated as of April 5, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed May 16, 2022)

Exhibit 10.1 April 5, 2022 Paul Stellato Dear Paul, We are pleased to offer you the position of Vice President, Controller and Chief Accounting Officer for Zimmer Biomet Holdings, Inc., reporting to me. In this position, you will be paid a gross annual salary of $375,000 in bi-weekly installments and your salary grade will be Z05. Your position is exempt, as such, your annual salary is intended to

May 16, 2022 EX-10.4

Form of Confidentiality, Non-Competition and Non-Solicitation Agreement with Paul Stellato (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed May 16, 2022)

Exhibit 10.4 CORPORATE EXECUTIVE CONFIDENTIALITY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT This Corporate Executive Confidentiality, Non-Competition and Non-Solicitation Agreement (?Agreement?) is made by and between Zimmer, Inc., a corporation having its principal headquarters in Warsaw, Indiana, and (?Employee?). Recitals A. For purposes of this Agreement, the term ?Company? means Zimmer,

May 16, 2022 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commissi

May 5, 2022 EX-10.4

Fourth Amendment and Limited Waiver, dated as of January 19, 2022, between Zimmer Biomet G.K. and Sumitomo Mitsui Banking Corporation, to the JP¥11,700,000,000 Amended and Restated Term Loan Agreement dated as of September 22, 2017, as amended by the First Amendment dated as of January 10, 2018, the Second Amendment and Limited Waiver dated as of February 25, 2020 and the Third Amendment dated as of April 28, 2020

EXHIBIT 10.4 FOURTH AMENDMENT AND LIMITED WAIVER (the "Fourth Amendment"), dated as of January 19, 2022, between ZIMMER BIOMET G.K. (the "Borrower") and SUMITOMO MITSUI BANKING CORPORATION (the "Bank"), to the JP?11,700,000,000 AMENDED AND RESTATED TERM LOAN AGREEMENT dated as of September 22, 2017, as amended by the First Amendment dated as of January 10, 2018, the Second Amendment and Limited Wa

May 5, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 Commission File Number 001-16407 Z

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation o

May 5, 2022 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of March 31, 2022 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International Orthopedics, LLC Delaware Biomet In

May 5, 2022 EX-10.3

Third Amendment and Limited Waiver, dated as of January 19, 2022, between Zimmer Biomet G.K. and Sumitomo Mitsui Banking Corporation, to the JP¥21,300,000,000 Term Loan Agreement dated as of September 22, 2017, as amended by the First Amendment and Limited Waiver dated as of February 25, 2020 and the Second Amendment dated as of April 28, 2020

EXHIBIT 10.3 THIRD AMENDMENT AND LIMITED WAIVER (the "Third Amendment"), dated as of January 19, 2022, between ZIMMER BIOMET G.K. (the "Borrower") and SUMITOMO MITSUI BANKING CORPORATION (the "Bank"), to the JP?21,300,000,000 TERM LOAN AGREEMENT dated as of September 22, 2017, as amended by the First Amendment and Limited Waiver dated as of February 25, 2020 and the Second Amendment dated as of Ap

May 5, 2022 EX-10.2

Amended and Restated Zimmer Biomet Deferred Compensation Plan, effective as of January 1, 2022 (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed May 5, 2022)

EXHIBIT 10.2 ZIMMER BIOMET DEFERRED COMPENSATION PLAN Effective as of January 1, 2022 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND CONSTRUCTION 1 1.1 Definitions.. 1 1.2 Rules of Construction. 5 ARTICLE II. PARTICIPATION 5 2.1 In General. 5 2.2 Participation. A 5 2.3. Transferred Employees. 6 2.4. Amendment of Eligibility Criteria.. 6 ARTICLE III. DEFERRAL ELECTIONS AND COMPANY MATCHING CONTR

May 5, 2022 EX-10.1

Amendment to Restated Zimmer Biomet Holdings, Inc. Executive Severance Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed May 5, 2022)

EXHIBIT 10.1 Amendment to the Zimmer Biomet Holdings, Inc. Executive Severance Plan Whereas, Zimmer Biomet Holdings, Inc. (the ?Company?) established and maintains the Zimmer Biomet Holdings, Inc. Executive Severance Plan (the ?Plan?), as effective May 14, 2018; and Whereas, the Plan delegates the Compensation and Management Development Committee (the ?Compensation Committee?) with the authority t

May 3, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Employer of

May 3, 2022 EX-99.1

Zimmer Biomet Announces First Quarter 2022 Financial Results

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces First Quarter 2022 Financial Results ? First quarter net sales from continuing operations of $1.663 billion increas

April 28, 2022 EX-99.1

ZIMMER BIOMET HOLDINGS, INC.

Exhibit 99.1 As previously announced, on March 1, 2022, Zimmer Biomet Holdings, Inc. (the ?Company?) completed the separation (the ?Separation?) of its spine and dental businesses through the distribution by the Company of 80.3% of the outstanding shares of common stock of ZimVie Inc. (?ZimVie?) to the Company?s stockholders at the close of business on February 15, 2022 (the ?Record Date?). The di

April 28, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Employer

April 8, 2022 SC 13G/A

ZBH / Zimmer Biomet Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Zimmer Biomet Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 98956P102 Date of Event Which Requires Filing of this Statement: March 31, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fil

March 29, 2022 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registr

DEFA14A 1 d260779ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as

March 29, 2022 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registr

DEF 14A 1 d260779ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Com

March 29, 2022 DEF 14A

PDF OF DEFINITIVE PROXY STATEMENT

March 1, 2022 EX-10.10

Waiver, dated as of February 25, 2022, by and between Zimmer Biomet Holdings, Inc., the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent.

EX-10.10 12 d650132dex1010.htm EX-10.10 Exhibit 10.10 WAIVER dated as of February 25, 2022 (this “Waiver”), to the 364-DAY REVOLVING CREDIT AGREEMENT dated as of August 20, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among ZIMMER BIOMET HOLDINGS, INC., a Delaware corporation (the “Borrower”), the LENDERS party hereto and JPMORGAN CHASE

March 1, 2022 EX-10.7

Reverse Transition Manufacturing and Supply Agreement, dated as of March 1, 2022, by and between Zimmer, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.7 to the Registrant’s Current Report on Form 8-K filed March 1, 2022)

Exhibit 10.7 REVERSE TRANSITION MANUFACTURING AND SUPPLY AGREEMENT dated as of March 1, 2022 by and between ZIMVIE INC. and ZIMMER, INC. Table of Contents Page ARTICLE I DEFINITIONS; RULES OF CONSTRUCTION 1 1.1 Definitions 1 1.2 Other Terms 4 1.3 Rules of Construction 4 ARTICLE II MANUFACTURING 4 2.1 General 4 2.2 Purchase Obligation 4 2.3 Volume Limitation; Capacity; Projects 5 2.4 Product Improv

March 1, 2022 EX-10.1

Tax Matters Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed March 1, 2022)

Exhibit 10.1 TAX MATTERS AGREEMENT DATED AS OF MARCH 1, 2022 BY AND BETWEEN ZIMMER BIOMET HOLDINGS, INC. AND ZIMVIE INC. Table of Contents Page TAX MATTERS AGREEMENT 1 RECITALS Section 1. Definition of Terms 2 Section 2. Allocation of Tax Liabilities 10 Section 2.01 General Rule 10 Section 2.02 Allocation of United States Federal Income Taxes and Federal Other Tax 10 Section 2.03 Allocation of Sta

March 1, 2022 EX-10.6

Transition Manufacturing and Supply Agreement, dated as of March 1, 2022, by and between Zimmer, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.6 to the Registrant’s Current Report on Form 8-K filed March 1, 2022)

Exhibit 10.6 TRANSITION MANUFACTURING AND SUPPLY AGREEMENT dated as of March 1, 2022 by and between ZIMMER, INC. and ZIMVIE INC. Table of Contents Page ARTICLE I DEFINITIONS; RULES OF CONSTRUCTION 1 1.1 Definitions 1 1.2 Other Terms 5 1.3 Rules of Construction 5 ARTICLE II MANUFACTURING 5 2.1 General 5 2.2 Purchase Obligation 5 2.3 Volume Limitation; Capacity; Projects 5 2.4 Product Improvements,

March 1, 2022 EX-10.2

Employee Matters Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed March 1, 2022)

Exhibit 10.2 EMPLOYEE MATTERS AGREEMENT BY AND BETWEEN ZIMMER BIOMET HOLDINGS, INC. AND ZIMMER BIOMET SPINE, INC. DATED AS OF MARCH 1, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.01 Defined Terms 1 Section 1.02 References, Interpretation 5 Section 1.03 Relation to Other Documents 5 ARTICLE II GENERAL PRINCIPLES 6 Section 2.01 Allocation of Assets and Liabilities 6 Section 2.02 Em

March 1, 2022 EX-10.8

Transitional Trademark License Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.8 to the Registrant’s Current Report on Form 8-K filed March 1, 2022)

EX-10.8 10 d650132dex108.htm EX-10.8 Exhibit 10.8 Dated March / 1 / 2022 TRANSITIONAL TRADEMARK LICENSE AGREEMENT by and between ZIMMER BIOMET HOLDINGS, INC. and ZIMVIE INC. TABLE OF CONTENTS 1. Definitions 1 2. License Grant 3 3. Restrictions 5 4. Ownership 6 5. Quality Control 6 6. Representations and Warranties; Covenants 7 7. Limitation of Liability 8 8. Confidentiality 8 9. Term and Terminati

March 1, 2022 EX-10.9

Waiver, dated as of February 25, 2022, by and between Zimmer Biomet Holdings, Inc., the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent.

Exhibit 10.9 WAIVER dated as of February 25, 2022 (this ?Waiver?), to the FIVE-YEAR REVOLVING CREDIT AGREEMENT dated as of August 20, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the ?Credit Agreement?), among ZIMMER BIOMET HOLDINGS, INC., a Delaware corporation (the ?Borrower?), the LENDERS party hereto and JPMORGAN CHASE BANK, N.A., as the Administrative Agen

March 1, 2022 EX-99.1

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zi

Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Completion of ZimVie Spinoff WARSAW, IN (March 1, 2022) ? Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a globa

March 1, 2022 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commiss

March 1, 2022 EX-10.3

Transition Services Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed March 1, 2022)

Exhibit 10.3 TRANSITION SERVICES AGREEMENT This Transition Services Agreement (this ?Agreement?) is entered into as of March 1, 2022 (the ?Effective Date?), by and between Zimmer Biomet Holdings, Inc., a corporation organized under the laws of the State of Delaware (?Parent?), and ZimVie Inc., a corporation organized under the laws of the State of Delaware (?SpinCo?). Parent and SpinCo are each re

March 1, 2022 EX-10.5

Stockholder and Registration Rights Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed March 1, 2022)

Exhibit 10.5 STOCKHOLDER AND REGISTRATION RIGHTS AGREEMENT BY AND BETWEEN ZIMMER BIOMET HOLDINGS, INC. AND ZIMVIE INC. DATED AS OF MARCH 1, 2022 TABLE OF CONTENTS Page Article I DEFINITIONS 1 Article II REGISTRATION RIGHTS 5 Section 2.01 Registration 5 Section 2.02 Piggyback Registrations 8 Section 2.03 Registration Procedures 9 Section 2.04 Underwritten Offerings or Exchange Offers 13 Section 2.0

March 1, 2022 EX-2.1

Separation and Distribution Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed March 1, 2022)

Exhibit 2.1 SEPARATION AND DISTRIBUTION AGREEMENT BY AND BETWEEN ZIMMER BIOMET HOLDINGS, INC. AND ZIMVIE INC. DATED AS OF MARCH 1, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 ARTICLE II THE SEPARATION 15 2.1 Transfer of Assets and Assumption of Liabilities 15 2.2 SpinCo Assets; Parent Assets 17 2.3 SpinCo Liabilities; Parent Liabilities 19 2.4 Deferred Markets. 21 2.5 Approvals and Notific

March 1, 2022 EX-10.4

Intellectual Property Matters Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed March 1, 2022)

Exhibit 10.4 Dated March / 1 / 2022 Intellectual Property Matters Agreement between ZIMMER BIOMET HOLDINGS, INC. and ZIMVIE INC. TABLE OF CONTENTS 1. Definitions 1 2. License Grants 4 3. Intellectual Property 5 4. Representations and Warranties; Covenants 7 5. LIMITATION OF LIABILITY 7 6. Confidentiality 7 7. Residual Knowledge 8 8. Term and Termination; Remedies 9 9. Miscellaneous 9 INTELLECTUAL

February 25, 2022 EX-25.1

Statement of Eligibility of Computershare Trust Company, N.A. on Form T-1 for Debt Securities.

Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) N

February 25, 2022 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2021 Commission file number 001-16407 ZIMMER BIOMET HOL

I have UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2021 Commission file number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State of Incorporation) (IRS Employer Identification No

February 25, 2022 EX-FILING FEES

Calculation of Filing Fee Table.

EX-FILING FEES 5 d194472dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximu

February 25, 2022 EX-10.40

Form of Restricted Stock Unit Award Agreement (three-year vesting) under the Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan (incorporated by reference to Exhibit 10.40 to the Registrant’s Annual Report on Form 10-K filed February 25, 2022)

Exhibit 10.40 ZIMMER BIOMET HOLDINGS, INC. 2009 STOCK INCENTIVE PLAN THREE-YEAR RESTRICTED STOCK UNIT AWARD Zimmer Biomet Holdings, Inc. (the ?Company?) granted you this restricted stock unit (?RSU?) award (?Award?) pursuant to the Company?s 2009 Stock Incentive Plan (?Plan?). Each RSU represents an unfunded, unsecured promise by the Company to deliver one share of Common Stock (?Share?) to you, s

February 25, 2022 EX-10.38

Form of Performance-Based Restricted Stock Unit Award Agreement (2022) under the Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan (incorporated by reference to Exhibit 10.38 to the Registrant’s Annual Report on Form 10-K filed February 25, 2022)

Exhibit 10.38 ZIMMER BIOMET HOLDINGS, INC. 2009 STOCK INCENTIVE PLAN THREE-YEAR PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD Zimmer Biomet Holdings, Inc. (the ?Company?) grants you this restricted stock unit (?RSU?) award (?Award?) pursuant to the Company?s 2009 Stock Incentive Plan (?Plan?). Each RSU represents an unfunded, unsecured promise by the Company to deliver one share of Common Stock (?

February 25, 2022 EX-10.34

Form of Nonqualified Stock Option Award Agreement (three-year vesting) under the Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan (incorporated by reference to Exhibit 10.34 to the Registrant’s Annual Report on Form 10-K filed February 25, 2022)

Exhibit 10.34 ZIMMER BIOMET HOLDINGS, INC. 2009 STOCK INCENTIVE PLAN THREE-YEAR NONQUALIFIED STOCK OPTION GRANT Zimmer Biomet Holdings, Inc. (the ?Company?) grants you this option (this ?Option?) to purchase fully paid and non-assessable shares of the Company?s common stock, par value $0.01 per share (the ?Common Stock?) pursuant to the Company?s 2009 Stock Incentive Plan (the ?Plan?), subject to

February 25, 2022 EX-21

List of Subsidiaries of Zimmer Biomet Holdings, Inc.

Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of December 31, 2021 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet 3i, LLC Florida dba Zimmer Biomet Dental Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biome

February 25, 2022 EX-4.1

Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 31, 2021

Exhibit 4.1 Description of the Registrant?s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2021, Zimmer Biomet Holdings, Inc. (the ?Company,? ?we,? ?our? and ?us? refer solely to Zimmer Biomet Holdings, Inc.) maintained four classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): (1

February 25, 2022 S-3ASR

As filed with the Securities and Exchange Commission on February 25, 2022

Table of Contents As filed with the Securities and Exchange Commission on February 25, 2022 Registration No.

February 22, 2022 8-K

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Com

February 22, 2022 EX-99.1

INFORMATION STATEMENT ZimVie Inc.

Exhibit 99.1 February 15, 2022 Dear Zimmer Biomet Stockholder: We previously announced plans to separate our spine and dental businesses from our core orthopedic businesses. The separation will occur by means of a spin-off of a newly formed company named ZimVie Inc. (?ZimVie?), which will own the assets and liabilities associated with our spine and dental businesses. Zimmer Biomet Holdings, Inc. (

February 10, 2022 SC 13G/A

ZBH / Zimmer Biomet Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Zimmer Biomet Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 98956P102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is

February 7, 2022 8-K

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Comm

February 7, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Comm

February 7, 2022 EX-99.1

Investor Day February 7, 2022

Exhibit 99.1 Investor Day February 7, 2022 Disclaimer FORWARD-LOOKING STATEMENTS AND NON-GAAP MEASURES Safe Harbor Statement under the Private Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies or prospects. We generally use t

February 7, 2022 EX-99.1

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zi

Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Fourth Quarter and Full-Year 2021 Financial Results ? Fourth quarter net sales of $2.038 billion decreased 2.3% and

February 7, 2022 EX-99.2

Zimmer Biomet Announces Expected Completion Date of March 1, 2022 for Spinoff of ZimVie

Exhibit 99.2 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Expected Completion Date of March 1, 2022 for Spinoff of ZimVie ? ?When-issued? trading of ZimVie common stock expe

February 7, 2022 EX-99.2

ZimVie Hosts Inaugural Investor Day; Provides 2022 Financial Outlook

Exhibit 99.2 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Zimmer Biomet Media Zimmer Biomet Investors Meredith Weissman Keri Mattox 703-346-3127 215-275-2431 [email protected] [email protected] Ezgi Yagci 617-549-2443 [email protected] ZimVie Media ZimVie Investors Laura Driscoll Marissa Bych 774-284-1606 805-305-1244 [email protected] m

January 28, 2022 SC 13G

ZBH / Zimmer Biomet Holdings Inc / JPMORGAN CHASE & CO - FILING ZIMMER BIOMET HOLDINGS, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ZIMMER BIOMET HOLDINGS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 98956P102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa

November 30, 2021 8-K

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2021 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Emplo

November 30, 2021 EX-99.2

Zimmer Biomet Announces Pricing of its Tender Offers for Certain Outstanding Debt Securities

Exhibit 99.2 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Pricing of its Tender Offers for Certain Outstanding Debt Securities (WARSAW, IN) November 30, 2021?Zimmer Biomet H

November 30, 2021 EX-99.1

Zimmer Biomet Announces Early Results and Upsize of its Tender Offers for Certain Outstanding Debt Securities

Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Early Results and Upsize of its Tender Offers for Certain Outstanding Debt Securities (WARSAW, IN) November 30, 202

November 24, 2021 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2021 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Com

November 24, 2021 S-8

As filed with the Securities and Exchange Commission on November 24, 2021

As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.

November 24, 2021 S-8 POS

As filed with the Securities and Exchange Commission on November 24, 2021

As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.

November 24, 2021 EX-4.2

Eighth Supplemental Indenture, dated as of November 24, 2021, between Zimmer Biomet Holdings, Inc. and Computershare Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 24, 2021)

Exhibit 4.2 EXECUTION VERSION ZIMMER BIOMET HOLDINGS, INC. $850,000,000 1.450% Notes due 2024 $750,000,000 2.600% Notes due 2031 EIGHTH SUPPLEMENTAL INDENTURE Dated as of November 24, 2021 to Indenture dated as of November 17, 2009 COMPUTERSHARE TRUST COMPANY, N.A. Trustee Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Application of this Eighth Supplemen

November 24, 2021 S-8 POS

As filed with the Securities and Exchange Commission on November 24, 2021

As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.

November 18, 2021 EX-1.1

Underwriting Agreement, dated as of November 15, 2021, among Zimmer Biomet Holdings, Inc., Barclays Capital Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, BNP Paribas Securities Corp. and BofA Securities, Inc.

Exhibit 1.1 EXECUTION VERSION $1,600,000,000 Zimmer Biomet Holdings, Inc. $850,000,000 1.450% Notes due 2024 $750,000,000 2.600% Notes due 2031 Underwriting Agreement New York, New York November 15, 2021 Barclays Capital Inc. Citigroup Global Markets Inc. Goldman Sachs & Co. LLC BNP Paribas Securities Corp. BofA Securities, Inc. As representatives of the several underwriters named in Schedule I he

November 18, 2021 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Com

Other Listings
AT:ZBH
IT:1ZBH 91,00 €
MX:ZBH
GB:0QQD
DE:ZIM 89,54 €
CH:ZBH
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista